<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Hormone replacement therapy increases the risk of developing <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> in postmenopausal women </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:mp ids='MP_0001858'>intestinal inflammation</z:mp> predisposes to <z:hpo ids='HP_0003003'>colon cancer</z:hpo> development, but effects of female hormones on <z:hpo ids='HP_0002583'>colitis</z:hpo>-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development have not been examined </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: To investigate the role of female hormones in the <z:chebi fb="0" ids="52071">dextran</z:chebi> <z:chebi fb="0" ids="32149">sodium sulfate</z:chebi> (DSS)-azoxymethane (AOM) mouse model for <z:hpo ids='HP_0002583'>colitis</z:hpo>-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: We performed ovariectomies, or sham operations, on mice, and supplemented these animals with indicated hormones </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, we used <z:chebi fb="67" ids="50114">oestrogen</z:chebi> receptor α or β (Erα or Erβ) mutant mice </plain></SENT>
<SENT sid="5" pm="."><plain>To study <z:hpo ids='HP_0002583'>colitis</z:hpo> or <z:hpo ids='HP_0002583'>colitis</z:hpo>-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, we used DSS only, or DSS and AOM, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Ovariectomy protects female mice against <z:hpo ids='HP_0002583'>colitis</z:hpo>-associated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> development </plain></SENT>
<SENT sid="7" pm="."><plain>Hormone replacement in ovariectomised mice with either <z:chebi fb="0" ids="23965">oestradiol</z:chebi> (E2), <z:chebi fb="0" ids="6716">medroxyprogesterone acetate</z:chebi> or a combination of both suggests that <z:chebi fb="2" ids="50114">oestrogens</z:chebi> are the ovary-derived factor that promotes <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> development in the context of inflammatory damage </plain></SENT>
<SENT sid="8" pm="."><plain>E2-treated animals showed increased clinical symptoms and Il-6 production upon DSS-induced <z:hpo ids='HP_0002583'>colitis</z:hpo> and enhanced epithelial proliferation </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment with E2 markedly increased the numbers of <z:mpath ids='MPATH_491'>polyps</z:mpath> in ovariectomised mice and also strongly promoted <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumour progression</z:e> with <z:hpo ids='HP_0000001'>all</z:hpo> E2-treated animals developing at least one invasive <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, whereas, placebo-treated animals developed <z:mpath ids='MPATH_270'>adenomas</z:mpath> only </plain></SENT>
<SENT sid="10" pm="."><plain>Using Er mutant mice, we find that the protumorigenic effect of <z:chebi fb="67" ids="50114">oestrogen</z:chebi> depends on both Erα and Erβ </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Our results suggest that <z:chebi fb="2" ids="50114">oestrogens</z:chebi> promote <z:mp ids='MP_0001845'>inflammation</z:mp>-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development by impairing the mucosal response to inflammatory damage </plain></SENT>
</text></document>